That clinical trials list doesn't mention the GAIN phase 2/3 trial [1] [2] currently underway to test COR388 from Cortexyme [3]. It's a small molecule that tar

That clinical trials list doesn't mention the GAIN phase 2/3 trial [1] [2] currently underway to test COR388 from Cortexyme [3]. It's a small molecule that targets gingipains, cysteine proteases of the P. gingivalis, a periodontal pathogen responsible for gingivitis that has been found in Alzheimer's patients. Here [4] is a paper on the gingivalis hypothesis funded by Cortexyme. [1] https://clinicaltrials.gov/ct2/show/NCT03823404?term=NCT03823404&draw=2&rank=1 https://clinicaltrials.gov/ct2/show/NCT03823404?term=NCT0382... [2] https://gaintrial.com/en/about https://gaintrial.com/en/about [3] https://www.cortexyme.com/?page_id=6022 https://www.cortexyme.com/?page_id=6022 [4] https://advances.sciencemag.org/content/5/1/eaau3333 https://advances.sciencemag.org/content/5/1/eaau3333